Drug Trial Radar · NCT06202989
Multiprofen-CC™ to Reduce Pain After Total Knee Arthroplasty
Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
306
Actual
Start
Sep 9, 2024
Primary completion
May 5, 2026
Study completion Jun 19, 2026
Sponsor
- Lead sponsor
- KAZM Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- Collaborators
- McMaster University
- First posted
- Jan 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Total knee arthroplasty is a surgical treatment which involves replacing the damaged articular cartilage of the knee joint with an artificial prosthetic in end-stage knee osteoarthritis. Although total knee arthroplasties are mostly successful, approximately 1 in 5 patients are unsatisfied with their outcomes with 16-33% of patients of patients experiencing lasting pain following total knee arthroplasty. Multiprofen-CC™ is a compounded topical analgesic currently available to healthcare professionals for prescription in patients experiencing localized musculoskeletal pain. To date there has been no evidence-based guidance generated to evaluate the efficacy of Multiprofen-CC™ in osteoarthritis patients. This study will test, in patients with end-stage knee osteoarthritis undergoing total knee arthroplasty, if the use of topical Multiprofen-CC™ in addition to standard of care pain management is more effective in controlling knee pain and reducing opioid use compared to placebo plus standard care alone.
Conditions
- Postsurgical Pain
Interventions
Multiprofen-CC™ plus standard treatmentDrug
Multiprofen-CC™ \[ketoprofen (10%), baclofen (5%), amitriptyline (2%), and lidocaine (5%)\] Dose: 1.0g, 3 times per day for 6 weeks after surgery
Placebo plus standard treatmentOther
The placebo is the base cream with no medicinal ingredients to be applied 3 times per day for 6 weeks after surgery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Acute postoperative painTime frame: 1, 2, 3, 4, 5, and 6 weeks postop
Locations
1 site in 1 country. Site status is shown where the registry gives one.
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.